XOMA Royalty Corporation Declares Cash Dividends
XOMA Royalty Corporation has recently announced a significant update regarding its Series A and Series B Cumulative Preferred Stock dividends. The company’s Board of Directors has authorized the payment of these cash dividends, showcasing its commitment to providing value to its shareholders.
Details of the Dividend Announcement
For the holders of the 8.625% Series A Cumulative Perpetual Preferred Stock, a cash dividend of $0.53906 per share will be distributed. This action highlights XOMA Royalty's dedication to ensuring that its preferred shareholders benefit directly from its ongoing financial successes.
Additionally, those holding depositary shares that represent 1/1000 of a share of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive a cash dividend of $0.52344 per depositary share; a decision that underlines the company's strategic approach to maintaining strong investor relations.
Payment Timeline and Record Date
The preferred dividends are set to be disbursed on or about October 15, 2025, with the eligible holders of record recognized as of the close of business on October 3, 2025. This timeline is provided to ensure that all eligible shareholders are informed and prepared to receive their dividends in a timely manner.
About XOMA Royalty Corporation
XOMA Royalty Corporation is notably a pioneer in the biotechnology field, functioning as a royalty aggregator. This unique role allows the company to assist other biotech enterprises in their mission to elevate human health outcomes. By acquiring the potential future economic benefits tied to pre-commercial and commercial therapeutic candidates, XOMA Royalty helps its partners achieve their developmental goals.
Funding Mechanism and Benefits
When XOMA Royalty acquires these future economic rights, sellers gain access to non-dilutive, non-recourse funding. Such capital can be crucial for advancing their own drug development efforts or for general corporate purposes, further enhancing the ecosystem of biotechnology innovation.
XOMA's Asset Portfolio
XOMA boasts an extensive and expanding portfolio of therapeutic candidates. These assets are defined as the rights to receive potential future economic returns associated with the advancement of various therapeutic projects. It is essential to note the importance of these assets as they play a critical role in supporting ongoing development and ultimately, patient care.
Current Therapeutic Interests
Within its portfolio, XOMA Royalty includes products like VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate vaginal gel 2%), IXINITY® (coagulation factor IX), and DSUVIA® (sufentanil sublingual tablet). However, it is crucial to understand that many of these assets remain investigational, with efficacy and safety not yet established. The path to commercialization for these compounds is still uncertain.
Contact Information for Investors
For inquiries related to investment and shares, stakeholders can reach out to Juliane Snowden at XOMA Royalty Corporation. With her experience and dedication, she ensures that investors are kept in the loop about financial developments.
For media-related queries, Kathy Vincent of KV Consulting & Management is available to provide insights and support, reinforcing XOMA's commitment to transparency and communication with all stakeholders.
Frequently Asked Questions
What are the declared cash dividends by XOMA Royalty Corporation?
XOMA Royalty Corporation declared a cash dividend of $0.53906 for Series A and $0.52344 for Series B Preferred Stock.
When will the dividends be paid out?
The dividends are scheduled to be paid on or about October 15, 2025.
Who is eligible to receive the dividends?
Holders of record as of October 3, 2025, will be eligible for the dividend payments.
What types of assets does XOMA Royalty have?
XOMA Royalty has a portfolio that includes both commercial and investigational therapeutic candidates, providing a diverse array of potential future economic returns.
How can investors get in touch with XOMA Royalty?
Investors can contact Juliane Snowden, while media inquiries can be directed to Kathy Vincent for assistance.
